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In vivo stimulation of IL-I 2 secretion by subcutaneous
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Summary Despite the well-demonstrated involvement of both interleukin 2 (IL-2) and interleukin 12 (IL-12) in the activation of host anti-
cancer response, the knowledge of IL-2-IL-12 interactions has still to be better investigated. This study was performed to evaluate the effects
of subcutaneous (s.c.) low-dose IL-2 on IL-12 secretion in metastatic cancer patients. The study included 19 evaluable metastatic renal cell
cancer patients, who received s.c. low-dose IL-2 (6 MIU day-' for 6 days per week for 4 weeks) as a first-line immunotherapy of their
metastatic disease. Serum levels of IL-12 were measured using an enzyme immunoassay on venous blood samples collected before the
immunotherapy and at 1-week intervals. The clinical response consisted of partial response (PR) in four and stable disease (SD) in eight
patients, whereas the other seven patients progressed. Mean serum levels of IL-12 observed in the overall patients significantly increased in
response to IL-2 injection. Moreover, by evaluating IL-12 variations in relation to the clinical response, a marked significant increase in IL-12
mean values occurred in patients with response or SD, whereas the progressing patients showed a significant decline in IL-12 levels during
IL-2 administration. Finally, IL-12 mean pretreatment values observed in patients who progressed were significantly higherthan those seen in
non-progressing patients. This study shows that low-dose IL-2 immunotherapy of cancer may stimulate the in vivo release of IL-12, and it
would suggest that IL-2-induced IL-12 enhancement is associated with a favourable prognosis.
Keywords: cancer immunotherapy; interleukin 2; interleukin 12
Interleukin 12 (IL-12) (Banks et al, 1995) and interleukin 2 (IL-2)
(Atzpodien and Kirchner, 1990) are the main anti-tumour
cytokines in humans. Several experiments have suggested the
evident anti-cancer efficacy of IL-12 (Banks et al, 1995), and
preliminary clinical studies (Del Vecchio et al, 1996) have
confirmed the capacity ofIL-12 to induce objective tumour regres-
sions, at least in melanoma patients. Because of its potential anti-
cancer efficacy, the evaluation of IL-12 endogenous secretion in
relation to the clinical course of the neoplastic disease could be
relevant. At present, the physiological regulatory mechanisms
responsible for IL-12 release need to be better investigated and
understood. Many endogenous substances evaluated have been
proven to inhibit IL-12 secretion, including cytokines, such as IL-
10 (Clerici and Clerici, 1996), and hormones, such as corticos-
teroids and catecholamines (Elenkov et al, 1997). In contrast,
exogenous substances, such as the bacterial product LPS, are able
to stimulate the production of IL-12 (Banks et al, 1995), whereas
no endogenous substance investigated has been shown to exert a
stimulatory action of IL-12 release. It is known that IL-12 is
mainly produced by dendritic cells (DC) and macrophages, which
may express intermediate-affinity IL-2 receptor (IL-2R)
(Caligiuri, 1993). Despite the well documented stimulatory effect
ofIL-2 on macrophage functions (Caligiuri, 1993), preliminary in
vitro studies have shown no stimulatory action of IL-2 on IL-12
production (D'Andrea et al, 1992). However, ithas to be taken into
consideration that the in vitro effects ofcytokines may be different
from the in vivo ones, because of the feedback structure of the
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cytokine network. An important feature of the immune system is
the way that the immunomodulatory effects of IL-2 depend on its
dosage. Different doses of IL-2 may activate the IL-2R with
different affinity for IL-2 (Caligiuri, 1993) and thus be responsible
for different profiles ofcytokine response.
This study was performed to evaluate the in vivo effects oflow-
dose IL-2 immunotherapy on IL-12 blood concentrations in
advanced cancer patients.
PATIENTS AND METHODS
The study included 20 consecutive histologically proven metastatic
renal cell cancer (RCC) patients (M/F ratio 14:6; median age 61
years, range 39-76 years), who underwent subcutaneous (s.c.) low-
dose IL-2 immunotherapy as the first-line therapy oftheir metastatic
disease. Dominant metastasis sites were as follows: soft tissues, two;
bone, seven; lung, nine; liver, two. The median Karnofsky score was
80 (60-100). No patient was under therapy with drugs influencing
the immune system during the study. Recombinant human IL-2,
supplied by Chiron (Amsterdam, Holland), was given s.c. at
6 x 106 IU day-' for 6 days per week for 4 consecutive weeks,
corresponding to one complete immunotherapeutic cycle. In non-
progressing patients, a second cycle was repeated after a 21-day rest
period. Patients were considered as evaluable when they received at
least one complete immunotherapeutic cycle. The clinical response
was evaluated according to UICC (UICC, 1978) criteria.
Radiological investigations, including computerized tomography
(CT) scan and/or magnetic resonance (MR), were performed before
the onset of therapy and after each immunotherapeutic cycle. The
clinical response was confirmed by external reviewers.
To evaluate IL-12 secretion, venous blood samples were
collected in the morning before the onset oftherapy and at 1-week
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Figure 1 Schedule of one cycle of IL-2 and timing of blood sampling for
IL-12 evaluation
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Figure 2 Changes in mean serum levels of IL-12 during IL-2
immunotherapy in 19 evaluable metastatic renal cell cancer patients
intervals until the end of the first cycle of immunotherapy.
Moreover, in non-progressing patients, the investigation of IL-12
secretion was also planned for the second cycle of treatment.
Serum samples were obtained by centrifugation, and stored at
-70°C until assayed. Serum levels of IL-12 were measured by
the enzyme immunoassay using commercially available kits
(Medgenix Diagnostics, Bruxelles-Belgium). Intra-assay and
interassay coefficients of variation were less than 4% and 5%,
respectively. Normal values of IL-12 (95% confidence limits)
obtained in our laboratory were less than 89 pg ml-'. Data were
reported as mean ± s.e. The results were statistically analysed
using the chi-square test, the Student's t-test and the analysis of
variance, as appropriate.
RESULTS
The schedule of IL-2 cycle and the timing of blood sampling for
IL-12 detection are illustrated in Figure 1. Evaluable patients were
19 out of 20, with the last patient rapidly progressing before
concluding the first cycle of treatment. No patient achieved a
complete response. Partial response (PR) was achieved in 4 out of
19 (21%) patients, three of whom had lung metastases and the last
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Figure 3 Changes in mean serum levels of IL-12 during IL-2
immunotherapy in metastastatic renal cell cancer patients with response or
stable disease (n = 12) or with progressive disease (n = 7)
patient soft tissue locations as dominant metastatic sites. The
median time to progression was 8 months (2-13+). Stable disease
(SD) was obtained in 8 out of 19 (42%) patients (median duration
6 months, range 2-8), whereas the other 7 out of the 19 (37%)
patients had a progressive disease (PD).
Before the onset oftreatment, abnormally elevated serum levels
ofIL-12 were seen in 8 out of 19 (42%) patients, whereas the other
11 patients showed baseline values within the normal range, as
evaluated in relation to both age and sex. The changes in mean
concentrations of IL-12 found in the evaluable patients on IL-2
administration are illustrated in Figure 2. IL-2 injection induced a
progressive and statistically significant increase in IL-12 mean
serum levels with respect to the pretreatment concentrations.
However, by evaluating IL-12 profile in relation to the clinical
response, IL-12 mean concentrations showed a highly significant
increase in response to IL-2 only in patients with response or SD,
whereas its levels significantly decreased in patients who had a
PD. In more detail, an IL-2-induced increase in IL-12 values at
least greater than 50% with respect to the baseline values occurred
in 10 out of 12 patients with response or SD and in only two out of
seven patients with PD. According to the chi-square test, this
difference was statistically significant (P < 0.01). In the other five
patients with PD, IL-12 showed a decline greater than 30% in four
patients and no substantial variation in the remaining patient.
Figure 3 shows changes in IL-12 mean values observed during
IL-2 therapy in relation to the clinical response.
By considering IL-12 secretion after IL-2 administration in rela-
tion to its pretreatment values, a decrease in IL-12 levels greater
than 30% was observed in five out of eight patients showing
elevated concentrations of IL-12 before therapy, and only in 1 out
of 11 patients with normal baseline values ofIL-12; this difference
was statistically significant, as evaluated by the chi-square test
(P < 0.01). Moreover, the percentage of PD found in patients with
high pretreatment values of IL-12 was significantly higher with
respect to that seen in patients with normal levels of IL-12 before
therapy (2 out of 11 vs five out ofeight; P < 0.01). Finally, as illus-
trated in Figure 3, patients with PD showed significantly higher
mean pretreatment levels of IL-12 than patients with response or
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Figure 4 Changes in mean serum levels of IL-12 in metastatic renal cell
cancer patients (n = 11) during the first and the second IL-2
immunotherapeutic cycle
SD (168 ± 21 vs 92 ± 11 pg ml-'; P<0.05), as shown by the
Student's t-test.
Changes in IL-12 mean values observed during the first and the
second cycle of IL-2 are illustrated in Figure 4. The second cycle
was repeated after the 21-day rest period in 11 out of 12 non-
progressing patients, whereas the last patient discontinued the
treatment for personal reasons. According to the analysis of vari-
ance, IL-12 increase observed in response to the second IL-2 cycle
was not significantly different from that observed during the first
cycle of immunotherapy with IL-2.
DISCUSSION
In contrast to the results previously reported in vitro (D'Andrea et
al, 1992), this study shows that s.c. low-dose IL-2 may stimulate in
vivo the release of IL-12. Moreover, the results of this study seem
to suggest that IL-2-induced IL-12 secretion may have a
favourable prognostic significance, because of its association with
a clinical efficacy of treatment, or at least with a stabilization of
the neoplastic disease. In addition, this study shows that IL-2-
induced stimulation of IL-12 secretion may occur more frequently
in patients with normal pretreatment levels of IL-12 itself than in
patients with abnormally high IL-12 levels before therapy.
Therefore, IL-12 secretion in response to IL-2 injection would not
simply represent a biological epiphenomenon, but it could play
a role in influencing the clinical response to IL-2 cancer
immunotherapy. In fact, on the basis of its anti-cancer activity
(Banks et al, 1995) and on its more frequent increase in non-
progressing patients, it is possible to hypothesize that the anti-
tumour efficacy of low-dose IL-2 regimen may be mediated at
least in part by an increased endogenous production of IL-12,
which has been seen to synergize with IL-2 in inducing objective
tumour regressions in experimental conditions (Wigginton et al,
1996). The hypothesis of the possible involvement of IL-12
endogenous secretion in influencing the anti-cancer efficacy of IL-
2 immunotherapy is also suggested by the evidence of no thera-
peutic result in cancer patients showing a decline in IL-12 levels in
response to IL-2 administration. The apparently paradoxical rela-
tion between high pretreatment levels of the anti-cancer cytokine
IL-12 and the lack of IL-2 efficacy could depend on the fact that
IL-12 blood levels tend to decrease on IL-2 immunotherapy in
patients with elevated IL-12 pretreatment values. The mechanisms
responsible for IL-2-induced increase or decrease in IL-12 levels
in relation to IL-12 concentrations before therapy need to be better
understood. The enhanced baseline endogenous production of IL-
12 could reflect a biologically precarious compensatory mecha-
nism activated by macrophages and/or DC of the host immune
system to counteract cancer growth. In these circumstances, a
further macrophage of DC activation by IL-12 would not give rise
to any further increase in IL-12 production, but only the release of
other cytokines often characterized by a suppressive function, such
as IL-6 and IL-10, with a resultant further suppression of anti-
cancer defences. The evaluation of gamma-interferon secretion in
successive studies could contribute to the better understanding of
the possible role of T helper- 1 lymphocytes in influencing IL-12
response to IL-2 injection. To date, it is notable that all cancer-
related cytokine alterations described are increases in blood levels
of suppressive cytokines, including IL-6 and IL-10, and/or of
abnormal declines in anti-tumour cytokine levels, such as IL-2
(Lissoni, 1996). Therefore, from a historical point of view, the
evidence of abnormally high levels ofthe anti-cancer cytokine IL-
12 in advanced cancer patients could constitute the first demon-
stration of possible immune compensatory mechanisms occurring
spontaneously with the progression of the neoplastic disease. In
addition, whereas most cytokine variations in response to IL-2
immunotherapy described up to now tend to reach a plateau after
the first weeks of IL-2 injection, IL-12 secretion seems to be
progressive in response to IL-2 and to be constant during that time,
as suggested respectively by the highest values of IL-12 at the end
ofthe cycle and by the similar profile ofIL-12 secretion during the
first and the second IL-2 cycle. Further studies will be required to
establish whether only low-dose IL-2 regimen may stimulate in
vivo the release of IL-12, or whether similar results may be
obtained by high-dose IL-2. This question is justified by the fact
that different doses of IL-2 may activate different types of IL-2R
(Caligiuri, 1993), with resultant differing immunomodulatory
effects. In any case, if successive studies confirm the prognostic
significance of IL-12 pretreatment levels and of its changes in
response to IL-2 therapy, the evaluation of IL-12 secretion is
recommended during IL-2 cancer immunotherapy; in addition, an
eventual decrease in IL-12 levels in response to IL-2 injection
could require a concomitant administration of IL-12 to obtain
therapeutic results.
In conclusion, this study shows that s.c. low-dose IL-2 may
stimulate in vivo the secretion of IL-12, and this event would be
associated with the clinical efficacy of treatment.
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